|
Dec 14
|
Biotech Stock Roundup: BLUE, CRSP & VRTX Get Gene Therapy Nod, ACAD Up on Patent News
|
|
Dec 14
|
Editas (EDIT) Licenses Cas9 Tool to Vertex, Stock Up 6%
|
|
Dec 14
|
Editas cashes in on CRISPR patent with Vertex deal
|
|
Dec 14
|
Ark Invest Stock Portfolio: 16 Biggest Positions
|
|
Dec 13
|
1 Biotech Stock That Could Be the Next Amgen
|
|
Dec 12
|
Here's What The FDA Approval Of Gene Editing For Sickle Cell Means For CRSP Stock And The Future Of Medicine
|
|
Dec 12
|
Could Intellia Therapeutics Become the Next CRISPR Therapeutics?
|
|
Dec 11
|
Why CRISPR Stock Keeps Falling
|
|
Dec 11
|
BLUE, CRSP & VRTX Down Despite FDA Nod to SCD Therapies
|
|
Dec 11
|
Sickle cell gene editing faces market hurdles: Analyst
|
|
Dec 11
|
After Golden Cross, CRISPR Therapeutics AG (CRSP)'s Technical Outlook is Bright
|
|
Dec 11
|
CRISPR (CRSP), Vertex Fall Despite FDA Nod to SCD Drug Casgevy
|
|
Dec 11
|
CRISPR Therapeutics and Dollar General have been highlighted as Zacks Bull and Bear of the Day
|
|
Dec 11
|
Is CRISPR Therapeutics a Good Stock to Buy Following Approval of Its First Drug?
|
|
Dec 11
|
Bull of the Day: CRISPR Therapeutics (CRSP)
|
|
Dec 11
|
Envista cut to Sell at Goldman Sachs, CRISPR to Underperform: 4 big analyst cuts
|
|
Dec 10
|
12 Best Genomics Stocks To Buy Now
|
|
Dec 10
|
Vertex Pharmaceuticals Just Proved Something Big to Investors. Time to Buy?
|
|
Dec 8
|
Vertex, CRISPR Therapeutics Get FDA Approval for First CRISPR Gene-Editing Therapy in US
|
|
Dec 8
|
Crispr Stock Whipsaws Lower After FDA Approves Gene-Editing Treatment
|